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1. Introduction 
 
Cell therapy is a technology that is pivotal to many new medical procedures that are incredibly 
beneficial. Many researchers have had great results using cell therapies to heal patients suffering in 
a number of ways. More specifically, human mesenchymal stem cells (hMSCs) have the potential to 
be turned into living tissue that can replace dead or damaged cells. These engineered cells are 
advantageous because they do not run the risk of being rejected by the patient. Research is 
currently being conducted, at Worcester Polytechnic Institute, on hMSCs to repair dead heart tissue 
that results from a heart attack. About 295,000 people year in the US suffer a myocardial infarction 
(out of hospital cardiac arrest) and a high percent must undergo invasive heart surgery to repair the 
damaged tissue. After a heart attack, part of the heart tissue dies. This dead tissue in the heart is 
very different from healthy living tissue. Dead heart tissue can be stiff and does not expand or 
contract very easily.  
The research being done at WPI uses fibrin microthreads as a delivery vehicle for hMSCs.  The 
current delivery device and bioreactor for these microthreads, a small piece of medical tubing with 
plastic clamps, is rudimentary in design. With continued success, this therapeutic cardiovascular 
procedure will soon move to clinical trials. There is currently no optimal way to prepare, ship, and 
store cells to be used in these types of procedures. Sterility, viability and safety are among a few of 
the major problems that must be addressed. Another aspect is the ease of use for the doctors who 
will be delivering the cells. The system currently being applied was designed simply with lab 
technicians in mind and does not take into account these crucial factors. Transporting the cells from 
the lab to the clinic, and their storage on site, must also be taken into consideration. 
If a device and system could be developed to account for these issues, than it would allow for the 
progression of many cell therapies and other techniques that are currently being studied. The goal 
of this project will be to design an efficient and safe system to get the cell seeded microthreads to 
the patient. An ideal method of storage and administration of the cell seeded microthreads will be 
developed.  
  
2. Literature Review 
 
2.1. The Heart 
 
The heart is a myogenic muscular organ that is found in all animals with a circulatory systemi. It is 
responsible for operating in conjunction with the circulatory system to pump blood and oxygen 
throughout the entire body. It is located in the chest cavity just behind the breastbone and in 
between the lungs, and it is divided into four main chambers (the left and right atria and the left 
and right ventricles). The atria receive the blood and the ventricles pump the blood from the 
heart to different organs in the bodyii. The heart is a vital organ that can be damaged by a 
variety of factors which lead to serious health problems such as myocardial infarctioniii. 
 
2.2 Myocardial Infarction 
 
Myocardial infarction, or a heart attack, generally occurs due to the interruption of blood supply to 
part of the heart. Damage occurs if blood flow is not restored to the organ within 20 to 40 minutes 
of the blockageiv. The result of blood interruption causes irreversible death of the heart muscle. A 
heart attack is usually due to the narrowing or blockage of a coronary artery. These blockages 
usually arise from a buildup of plaque or a rupture in the wall of the artery. Approximately one 
million Americans suffer a heart attack each year, and four hundred thousand of them die as a result 
of their heart attackv. Most heart attacks are minor and people ignore them because they confuse 
the chest pains with other problems. 
 Death is more likely to take place when symptoms are ignored and a more fatal attack occurs. 
When it comes to medical treatment, the aim is to unblock the affected artery and restore blood 
flow to the area of the heart in danger as soon as possible. Today there are many medicines that are 
used to reduce the chance of heart attack. Anti-platelet medicines, for example, are used to prevent 
the tendency of platelets to clot and cause blockagesvi. In severe cases defibrillators are used and 
open heart surgery is common. Transplants can be used if the heart is beyond saving, but there is a 
limited supply of donors. This is why there is so much funding going into research for new methods 
to treat heart failure. 
 
2.3 Mesenchymal Stem Cells  
 
Stem cells are very unique cells that can undergo differentiation into a variety of specialized cell 
types.  They can also maintain the ability to proliferate while maintaining the undifferentiated state.  
The discovery of human mesenchymal stem cells (hMSCs) has been a suggested pathway to bypass 
ethical hardships confronted by embryonic stem (ES) cell researchvii. Furthermore, while ES cells can 
theoretically differentiate into all of the cells in the body, HMSCs with their multipotent 
characteristics can be isolated from adult bone marrow and induced in vitro and in vivo to 
differentiate into an array of cells that constitute bone, cartilage, fat, muscle, and other kinds of 
connective tissue such as tendonviii. Bone marrow is considered the top candidate for isolation of 
mesenchymal stem cells because they exhibit a high congregation of MSCs while still remaining 
fairly accessible.  HMSCs can be obtained in large quantities, cultured, and frozen for preservation 
without losing their capacity to form a variety of cell types, including cardiomyocytes.  Credited to 
these versatile qualities, HMSCs are the best candidate for cell delivery for cardiac tissue among 
numerous adult stem cellsix.       
 
The goal in the implantation and experimentation of hMSCs is to manipulate them in such a way 
that they can express cardiogenic markers.  However, the techniques used to stimulate myogenic 
differentiation in hMSCs vary.  Experimental data produced by Strauer and colleagues in their study 
titled, Repair of Infarcted Myocardium by Autologous Intracoronary Mononuclear Bone Marrow Cell 
Transplantation in Humans, suggest that bone marrow-derived cells may contribute to the healing 
of myocardial infarction (MI)x. The method used in their study was to treat 10 patients by 
intracoronary transplantation of autologous, mononuclear bone marrow cells (BMCs) via balloon 
catheter in addition to standard therapy in another 10 patients after MI.  In the following 3 months, 
the infarct region had decreased significantly within the cell therapy group and was also significantly 
smaller compared with the standard therapy group.  While infarction wall movement velocity 
increased significantly only in the cell therapy group, further cardiac examinations that were 
performed for the cell therapy group showed significant improvement in  stroke volume index, left 
ventricular end-systolic volume and contractility, and myocardial perfusion of the infarct region.  
These results suggest that selective intracoronary transplantation of autologous, mononuclear BMCs 
is safe and seems to be effective under clinical conditionsxi.  
 
In a similar study titled, autologous bone-marrow stem-cell transplantation for myocardial 
regeneration, tests were concluded using the direct injection technique in six human patients. All of 
the patients had experienced MI and undergone coronary artery bypass grafting (CABG).  Surgeons 
injected up to 1.5×106 autologous AC133+ bone-marrow cells into the infarct border zone in each 
patient. In the following 3-9 months after the surgery, global left-ventricular function had improved 
in four of the patients, and infarct tissue perfusion had significantly improved in five of the patients. 
These results suggest implantation of AC133+ stem cells to the heart is safe and might induce 
angiogenesis, therefore improving perfusion of the infarcted myocardiumxii.  
 
2.4 Culturing hMSCs 
 
The hMSCs are first isolated a healthy donor.  The MSCs from the marrow sample can then be 
cultured and grown in a Petri dish containing human mesenchymal stem cell media with basil media 
and fetal bovine serum in order to acquire the cells needed for coculturing with human 
cardiomyocyte. Under culture conditions, when there is direct contact of cardiomyocytes and 
hMSCs, the hMSCs begin to express the cardiac specific proteins myosin heavy chain, β-actin, and 
Troponin-T.  During coculturing human cardiomyocytes can be labeled with a fluorescent indicator 
cell sorting and then mixed with the hMSCs in a smooth muscle medium and seeded at the desired 
cell density.  Cells should be cultured in an incubator at 37°C for duration of 48 hours.  Once 48 
hours has passed the cells can washed with buffered saline solution to remove excess fluorescent 
label.  Trypsin can be added to detach the cells from the surface of the Petri dishiv. 
 
2.5 Microthread Seeding Procedure 
 
The microthreads that are inserted into the heart must have a certain number of cells attached in 
order for them to be effective. There are many things that the cells will need in order to survive and 
adhere to the microthreads including, temperature, fresh media and a strong ECM (extracellular 
matrix). hMSCs are placed in to the bioreactor. The purpose of the bioreactor is to act as a stable 
environment for the cells to live and naturally adhere to the microthread rather than the 
surrounding walls.  
The exact procedure of seeding the microthreads involves many steps and different chemicals to 
feed cells, and hydrate the threads. The first step in the process is the removal of cells from a flask 
through the use of Trypsin. hMSCs are anchorage dependent and the Trypsin is an enzyme that will 
release the cells from the flask. Once returned to a stable environment the hMSCs will reanchor. 
Next the cells are spun in a centrifuge and the excess Trypsin is removed. The cells are then placed 
into a media that contains a serum containing proteins that will stop the actions of the Trypsin. 
Before the cells are placed in the bioreactor with the threads, the threads are hydrated in order to 
increase cell adhesion. Since the cells are super concentrated they require a large volume of media 
in the bioreactor in order to survive. Inefficient levels of media in the bioreactor can lead to high 
levels of waste which could be harmful to the cells and result in dead cells remaining adhered to the 
threads. The bioreactors are placed into a plastic vial which attaches to a rotator and the entire 
assembly is placed in an incubator. Currently the cells are incubated for approximately 24 hours 
before they are ready to be used for implementation.  
Different approaches to this process could be taken to perfect the cell seeding system. Larger 
volumes of media could be used while maintaining the same percentage of cells to possible yield a 
higher adhesion amount. There is also the possibility of having communal bioreactors in which 
multiple threads are seeded at once. Also the amount of time that the time they are incubated for 
has yet to be thoroughly researched.     
   
2.6 Tissue Engineering 
 
WPI’s microthreads are currently pending a US patent. They are created from collagen and fibrin 
using a thread model of in-vitro ACL scaffold regeneration. They are created to have similar 
mechanical and structural properties as collagen threads; they are made up of a structural protein 
that is found in the provisional matrix during wound healing. The focus of microthreads is to 
incorporate them into the process of complex ligament tissue engineering. 
Tissue engineering is a field of biomedical engineering which focuses on biomaterials and cells; also 
is known as regenerative medicine. Most tissue engineering involves biological functions, liquids and 
materials.  Some specific tissue engineering categories are bone, cartilage, and blood vessels. When 
focusing on one aspect scientists must look at the structural and mechanical properties that coincide 
with the specific aspect. When looking into each aspect one must research the tissue’s properties 
and work on improving their functions and growth. Using the properties researched and realizing 
the need for this specific field, much advancement has been made.  
One category of tissue engineering is called bone tissue engineering and works with the structure of 
the bone and properties it holds. Examining these properties they are then used to create bone 
supplements/substitutions. Many of the key factors that go along with bone tissue engineering are 
harvested cells, recombinant signaling molecules and 3D matrices. Using a scaffold to attach the 
harvested cells and improving the growth of the bone, one must make sure the cells will multiply 
and transform to where they contain bone-like properties. 
Since bone tissue engineering technologies have been emerging; more and more techniques have 
been discovered to work and not work. Some current methods of bone replacement are autografts, 
allografts, and metallic replacements. Within those replacements there have been some arising 
challenges, such as the amount of time it takes the cells to transform and survive on scaffold, design 
systems, complex scaffolds, and new biomaterials. 
Another category for tissue engineering focuses on the cartilage engineering. Cartilage is a tissue 
that can sometimes degenerate by causes of trauma and disease. However since this is a new focus 
for tissue engineering the current repair/treatment methods haven’t been perfected yet, but does 
hold a great promise in the future. The basic procedure that has come from cartilage engineering is 
the use of a biocompatible scaffold that holds the bioactive cells needed to differentiate the other 
cells. The best approach of cartilage engineering is using scaffolds that are created by natural and 
synthetic biomaterials. 
Over the past few years numerous advances have come out that pertain to cartilage tissue 
engineering. Such are cell–scaffold composites which are to help with the lack of cell retention rate. 
In addition the scaffold being used should almost be identical to what the repaired tissue is in order 
to be successful. A second advancement is the use of mesenchymal progenitor or stem cells for 
cartilage engineering. Using these cells provide less of a concern when looking at the donor site, 
lifespan and cell dedifferentiation. With these advancements already scientists are looking to 
overcome more challenges such as if the tissue has a hostile environment or if this can be combined 
with gene therapy.  
Blood vessel tissue engineering is becoming more and more important in the tissue engineering 
field. The approach to blood vessel engineering is recellularization, which occurs when one strips the 
living cells from the donor leaving the extra matrix as a scaffold. Once the scaffold is formed it is 
seeded with the new cells which are able to form back into the original tissue because of how the 
scaffold is structured. Recellularization is becoming more and more frequent in laboratories, and 
even in bone tissue engineering. One advancement scientist had discovered is using adult stem cells 
to created functional blood vessels that can later replace synthetic grafts which are usually require 
in vascular bypass surgeries. They had determined that one can build the blood vessel using the 
donor’s tissue and an animal’s adult stem cells, using these blood vessel the complications of the 
surgery would be reduced.  
Blood vessels have also been created another way which is to harvest skin cells and remove them 
leaving just the scaffold and used endothelial cells of the patients because they had discovered that 
the fibroblasts can clog the blood vessel. These endothelial cells are able to hold a smooth blood 
flow in the interior of the vessel created. Today blood vessel engineering is proven to be used in 
kidney dialysis and to have been effective and successful.  
Tissue engineering has clearly become an advancing study in the biomedical field. A great 
contribution to the reason it has been advancing so rapidly, is the need to transplant organs, and 
tissue growth/replacement. This specific type of engineering incorporates biologists, chemical 
engineers, material scientists, surgeons, and other clinical researchers, which is important because 
each role plays a key part in coming up with different tissue engineering procedures. The greatest 
advancement is the focus of skin tissue and the ability of skin grafts and using the patient’s own skin 
cells to repair the skin of patients with skin disorders or burn victims. However over the next few 
years there will be many obstacles that scientists must overcome such as the lifespan of the cells, 
how long it takes the tissue re-growth to become effective, how many times one must go through 
surgery, and if there is an immunity rejection when using a donor’s cells into a patient’s body. 
  
3. Project Strategy 
This project was completed in two stages, one being completed in December 2010 and the second 
in May 2011. The two stages were necessary because I would be graduating in December and my 
three group members would continue my research. My project would focus on improving the 
current design of the bioreactor, which had many issues. The rest of the team would continue my 
research and examine transportation methods and storage. Dr. Gaudette was an asset throughout 
the entire project and he played the roles of both client and advisor.  
 
3.1 Initial Client Statement 
 
The initial client statement was as follows: 
Design a system to deliver cell seeded microthreads to the clinic.  The system should consider 
storage on site; preparation prior to delivery and shelf life. 
 
3.2 Clarification of Initial Client Statement 
 
The initial client statement was a vague description of the problem that needed to be solved and it 
needed both clarification and specification. Extensive background research on relative topics, such 
as, stem cell research, cell culture and storage, cryopreservation, and standard operating 
procedures was done in order to gain a better understanding of the factors involved. Informal 
interviews were done with Dr. Gaudette as well as students who had been working directly with the 
original bioreactor were held to find limitations and dislikes. Some of the major concerns with this 
design involved an exposed needle that presented safety issues, as well as the two plastic clamps 
which made the device awkward to work with (see Figure 1). Up to this point, no research had 
looked into the longevity of the cells if kept in this bioreactor. After conducting this background 
research and having a more elaborate understanding of the device, we formulated a revised client 
statement: 
 Design a system of delivering cell seeded microthreads from the laboratory to the operating 
room of a clinic. This system should focus specifically on the time between arrival at the clinic and the 
time of insertion of cells into patient. This design must consider preparation prior to delivery to the 
patient and also provide a minimum shelf life of one week and storage on site. The final design must 
maximize cell viability while still guaranteeing safety to all the users involved. 
 
Figure 1 
  
4. Alternative Designs 
 
4.1 Objectives, Functions & Specifications 
 
From our research, and speaking with our client and potential users, we began to form list of 
objectives pertinent to our project: 
 Maintain cell viability 
 Safe 
 Device must be small 
 Short application/preparation time 
 Maximum shelf life 
 Environmentally Friendly 
 Simply Design/User Friendly 
After these objectives were then confirmed by our project advisor and client, Professor Gaudette, 
we began to develop specifications. To better understand each of the aspects involved with this 
project, the team evaluated all of the objectives, functions and constraints. To evaluate the 
importance of each of the objectives that were created, a pairwise comparison was conducted. This 
simple chart form of comparing ideas is a good way to rank objectives. Each member of the group 
completed a pairwise comparison and the results were merged and averaged to create an overall list 
of ranking. The top three ranking objectives were safety, cell viability and sterility and the lowest 
ranking objective was the ability to hold >1 microthread.  
Safety was ranked the most important objective involved in our project because without the 
wellbeing of the user and cells, our device would not be feasible. The original bioreactor design 
contained an exposed needle that created a serious safety concern for any one coming in contact 
with it. There is a lot of handling required with the bioreactor when it is being prepared for seeding 
and prior to surgery when the sutures are removed for implantation. If a technician or surgeon was 
punctured with this needle it would not only be a potential biohazard, but that particular suture 
would have to be disposed as well. Speaking with a student, Andrew Kazanovich, he noted that it 
was irritating and difficult at times to work around the exposed needle. The safety of the cells was 
another important aspect of safety that we worked on. The cells would to be kept from being 
shaken, exposed to extreme temperatures, UV light and other unwanted biological agents. The team 
began working solutions to this problem and created a list of ways that this safety condition could 
be improved. This list of safety concerns was broken into two categories, user and cell safety. A list 
of ways to promote safety in both situations was created:   
• Safety 
• Cell Safety 
• air tight packaging 
• durable packaging 
• bio-agents 
• temperature control  
• UV protective cover 
• minimize time out of incubator 
• O2 and CO2 regulation 
• User Safety 
• No exposure to cells 
• No exposed needles 
• magnet 
• hard cap/container 
• well or depression 
• "cork" 
• Sleeve  (with an antiseptic 
In order to maintain efficacy of the procedure, the cell viability would also have to be accounted for. The 
hMSCs need to be stored in a container that offered them protection from contamination from the 
environment. Our client wanted cells to be viable for up to a week, so the device would need to have 
the proper attributes to allow this. If the cells could not adhere to the microthread in the device or 
remain alive the device would be considered a failure. To protect the cells the device would also have to 
durable and not be affected by human contact.  Another function desired was the devices ability to hold 
more than a single microthread at one time. It was desired that the device would contain multiple 
threads and maintain viability. The options for a container that could hold multiple threads were either 
to have individual bioreactors or one large communal bioreactor.  
To maintain the life of the cells, the device needed to be sterilizable. We considered many methods of 
sterilization such as using an autoclave, ethylene oxide and cold sterilization.  If the device could not be 
sterilized, it would not be accepted under the guidelines of the FDA for a medical devicexiii. The 
sterilization is also necessary to stop and airborne pathogens or dirt that could hinder the cells.  
Although we were presented with minimal constraints, they were all vital for successfully completing 
this project. The main constraint we were confronted with was the time limit that we were given. The 
first section of this project needed to be completed within seven months. Since I would be graduating it 
was imperative that the project was completed by the previously stated deadline. Another constraint 
involved with our project was the monetary assistance that we were given, which was $156 per group 
member. Finally the size of the device was an important constraint that needed to be considered. Our 
device would need to be big enough to contain the microthreads and small enough to fit in a standard 
incubator. A small device size was also important to minimize the overall cost involved.  
 
4.2 Conceptual Designs 
 
After compiling a detailed list of functions and constraints our team began to create basic designs. 
Brainstorming sessions were held to develop possible designs for our device. For each specification we 
had we created a design that would facilitate it. Here are some of the conceptual designs that we 
created:  
 
Figure 2 
 [1) A circular 8 well bioreactor with cap.2) A rectangular 8 well bioreactor.3) A square single thread bioreactor.4) A square 
multiple thread bioreactor.]  
 
  
Figure 3 
[1) Disposable, individually packaged microthread, could use as many desired at one time. 2) Reusable, individually 
packaged microthread. 3) Petri dish style, 8 microthread, communal bioreactor.] 
 
A series of designs were considered including both communal and individual bioreactors.  After 
evaluating our conceptual designs it was decided that the final design would multiple tubes to contain a 
total of 8 microthreads. To achieve our size constraint, a cylindrical design would be utilized. A tapered 
end would be applied to the cylinder allowing it to be inserted into a standard rotisserie. The rotisserie 
machine is a piece of equipment that it used to aid in the process of seeding the cells the microthreads. 
The spinning of this device allows for constant movement of the cells and media inside the bioreactor, 
not allowing it to settle. This cylindrical design resembled the same shape as the previous bioreactor 
that was being used. Finally this design was chosen in order to maximize the ease of use for both the lab 
technicians and the surgeons.      
 
4.3 Final Design 
 
After choosing the different aspects from many conceptual designs, we formulated a preliminary design 
that would achieve the maximum number of functions. In order to create a prototype of this preliminary 
design, it needed to be drawn in using CAD software. Using Solidworks, the design of the prototype was 
created so that it could be processed by the Rapid Prototyping machine. The Rapid Prototyping machine 
has the ability to print 3D objects, layer by layer, out of plastic. A prototype would enable the team to 
examine the compatibility of the device with the microthreads and necessary equipment. Pictures of the 
drawings can be seen here:  
  
  
Figure 4 
 
Figure 5 
  
5. Design Verification 
 
Using the prototype as model, our group did preliminary testing on the final design that we had created. 
We examined the devices ability to hold eight sutures at a time. The size of the device was also 
examined to confirm that it would fit it necessary equipment such as a standard incubator and the 
rotisserie device. Ethylene oxide was a viable method of sterilization for this device. This design is not 
only durable but satisfies all of the functions required for maintaining cell viability. The needles rest in 
the grooves on the top of the device, preventing possible puncture by one of the users. The prototype 
standing alone and containing microthreads can be seen below.  
 
 
Figure 6 
 
Further design verification will be conducted by the remaining group members in the following months. 
A working prototype will be made to test the ability of this device to successfully seed microthreads with 
cells. The longevity of the cells in the bioreactor will also be determined by examining the amount of 
time that this device can remain on the shelf while keeping the cells alive.    
  
6. Discussion 
 
Previously the device being used as a bioreactor was complicated and needed a lot of developments. 
Our group met the objectives of designing a system for expediting and improving the process of 
preparing cell seeded microthreads for the clinic. The progression of this process is still ongoing 
however; we have already made significant improvements to this medical procedure. The remainder of 
this section will confirm that each of the objectives was met.  
User safety was improved by creating an area that will contain the needle and protect the users. With 
the needle safety placed into the “holster” that was created, it is difficult for an accidental puncture to 
occur when handled properly (Figure 7). The previous design used a flexible piece of plastic tubing that 
could damage the cells on the thread if squeezed. The new bioreactor is made out a strong plastic that 
can be constantly handled without damaging the cells or threads. Instead of holding a single 
microthread, this new design can hold eight at one time, which reduces the amount of time needed for 
not only seeding but also application. Since multiple sutures are needed for a single surgery this also 
reduces the number of materials involved in the process. All of the objectives of this project were 
completed on time and done within the stated budget. This design allows for an easier and more 
efficient system of preparing cell seeded microthreads for the clinic.  
 
6.1 Manufacturability, Ethics and Influences 
 
The price of the prototype that I had made was very inexpensive costing only about $15.00. This device 
was not only cheap but easy to manufacture because it can created within 12 hours. This bioreactor 
device design could be machined out of any material. All of the holes and physical aspects of the device 
can be machined using only a small number of machines including a drill and a reciprocating saw. A 
cheap and easy to produce device would create a low cost for not only laboratories but also for the 
patients receiving treatment. This device could be made out of any number of materials and does not 
require any hazardous or scarce materials.  
This device combined with microthreads inside it will offer a beneficial treatment for patients who have 
suffered a heart attack. This device will have a very positive societal impact because it will make the lives 
of all the users significantly easier. The simplicity of this device allows for a decreased preparation time 
by lowering the number of required materials. The communal design of this bioreactor, among other 
factors, will lower the application time which means a decrease in medical bills as well as a shorter 
recovery time.  
This product does pose any political concerns because it will help people live better lives. In terms of 
ethics, this medical device only presents effects as it will be in the technicians, doctors and patients best 
interest to use it. The device itself can only help people and will assist in creating a good and satisfying 
life. The communal bioreactor created for this project will house 8 microthreads that will be designed to 
regenerate dead tissue which lead to an increase in personal heath for many people.  
  
 
Figure 7 
7. Final Design & Validation 
 
The task given to this project tem was to create a bioreactor that would have better characteristics than 
the one previously in use. After conducting thorough background research and speaking with various 
users we developed our conceptual designs. The problems involved with the previous design were 
relatively obvious which allowed us to work quickly toward a final design that would solve these 
problems. Once we had moved on to our final design that allowed for the accommodation of 8 
microthreads it was an easy decision to have a rapid prototype made. This was a cheap and easy way to 
have a physical model of our test that could examined and used to conduct preliminary tests. The full 
project breakdown was done by creating a Gantt chart that dictated the dates that each section of work 
would be completed (Figure. 8).  
To test the appropriate size of the device to ensure that it would fir in the rotator device. It was found 
that the device could fit in the rotator but not easily as it was a little short. The device could easily hold 
the 8 sutures at any one time and they could be easily inserted and removed for seeding and 
application. The direct comparisons to the previous design result in less materials and equipment 
needed. Due to the cap involved with the device, there would no longer be an exposed needle which 
means that it would now be much safer. Finally this enclosed device would keep the cells protected and 
the needles sterile.   
 Figure 8 
  
8. Conclusions & Recommendations 
 
The first stage of this project has been successfully completed and the next stage is ready to commence. 
So far this group has developed a model of a working device that meets all of the functions and 
constraints that were desired. Overall the bioreactor, cell seeding process and the surgical application 
have been improved through the creation of this device.  This device improves the overall process of 
seeding microthreads and will also lead to developments in the future.   
In the continued research conducted by Dr. Glenn Gaudette and researchers, we have considered 
possible improvements that could be made to perfect this design. First, a cushion should be inserted 
into the center of the device that allows for the needles to stuck in place. This would hold the sutures in 
place during seeding which would potentially allow for better cell adhesion. It would also improve safety 
by preventing the needles from being exposed unexpectedly during use. Second, the aeration of the 
device could be improved because oxygen is necessary for the continued life of the cells. Without any 
circulation of air into the device, the cells would die. Finally, the device would ideally be able to remain 
on the shelf for an extended period of time to allow for a quicker application by removing the time 
involved with delivery. One potential solution to this would be to freeze the microthreads, while they 
are in the bioreactor.  
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